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Abstract
Introduction: Klebsiella pneumoniae is a gram negative enterobacteriaciae commonly associated with nosocomial infections. Multi-
drug resistant strains are increasingly being reported with corresponding increase in morbidity and mortality. The study outlines the
epidemiology and antibiotic resistance pattern of K. pneumonia over a 10 year period in Moi Teaching and Referral Hospital, Eldoret,
Kenya.
Methodology and Study Design: This is a retrospective analysis of all the blood culture results for K. pneumoniae isolates in the
hospital for the period 2002-2013.
Results: K. pneumoniae accounted for 23% of the hospital isolates (231/1356) during the study period; of these, 82.6% were from the
New Born Unit. Most of the isolates were multi drug resistant with highest resistance of over 80% to Penicillins, Cephalosporins,
Macrolides, Tetracyclines, Sulphonamides, Lincosamides and Chloramphenicol. Aminoglycoside and Quinolone resistance was also high
at 49.2% and 41.3% respectively. The lowest resistance rates were documented for Carbapenems (23.2%). For specific antibiotics, there
was high resistance to commonly used antibiotics (over 80% for Ceftriaxone, Cefipime, Gentamycin and Ceftazidime). The antibiotics
with least resistance were Amikacin and Meropenem (21% and 7 % respectively).
Conclusion: There was a high prevalence of multidrug resistant K. pneumoniae isolates in the hospital, the majority originated from the
New Born Unit. Resistance to third generation Cephalosporins and Gentamycin was high while Meropenem and Amikacin had the least
resistance.
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Introduction
Klebsiella pneumoniae is a gram negative, rod shaped bacterium belonging to the family Enterobacteriaceae. It has in recent
years become an important pathogen in nosocomial infections worldwide. Increasingly, many strains that are extended-spectrum β-
lactamase (ESBL) producing as well as Carbapenem resistant are being reported as causing outbreaks in hospitals and particularly in
intensive care units (ICUs) and New Born Units (NBUs) where there is great antibiotic pressure (Centers for Disease Control and
Prevention, 2003; George AJ et al., 2005). The spread of these nosocomial infections occur from patient to patient, healthcare workers to
patients and vice versa as well as contaminated hospital environment and equipment. Most of the infections occur in neonates, in
immunocompromised patients such as critically ill patients in ICU, patients with malignancies, patients on chemotherapy, HIV infected
patients and diabetic patients (Adamski J et al., 2008; Richards MJ et al., 1999; Winokur PL et al., 2001).
Treatment options for multi-drug resistant K. pneumonia (MDR KP) are limited; more so in resource constrained settings. Most
studies on MDR KP are from developed countries with scanty data from resource limited settings. The study objective was to describe
the epidemiology and antibiotic resistance pattern and trends for K. pneumoniae at Moi Teaching and Referral Hospital (MTRH) in
Eldoret, Kenya.
Materials and Methods
Moi Teaching and Referral Hospital (MTRH) is the second largest public hospital in Kenya. It hosts Moi University School of
Medicine and serves a catchment with population of about 16 million people. It has a microbiology laboratory that handles the culture
and sensitivity specimen in the hospital. Blood specimens were cultured in BACTEC 9120 and BACTEC 9050 (Becton-Dickinson, New
Jersey, USA) automated systems. Antibiotic sensitivity at the facility was performed by disc diffusion method and susceptibility reported
based on Clinical and Laboratory Standards Institute (CLSI) susceptibility criteria. The laboratory is International Organization for
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Standardization (ISO 15189) certified and has internal quality management systems in place. The culture results are manually
documented in a microbiology register provided by the Kenya Ministry of Health.
Ethical approval was sought from the MTRH/ Moi University Ethics and Review Board and from the Director of MTRH before the study
was conducted. The data was anonymized through unique study numbers and no patient identifiable information was collected.
This was a retrospective analysis of K. pneumoniae isolates in patients of MTRH for the period 2002 to 2013. Data is analyzed
using SAS version 9.3 (SAS Institute Inc., Cary, NC). Normality test is conducted using Shapiro and Wilks normality test. Categorical
variables are presented as frequencies and percentages while continuous variables are expressed as mean and standard deviation. Bar
charts and line graphs are used to present the pictorial distribution of organisms.
Results
Majority of the study samples were from female patients (64.8%). The median age was 5 days with interquartile range of 3-15
days (Table i). K pneumoniae accounted for 23 % of the total isolates during the study period (281/1231). It was the most prevalent
pathogenic isolate. It constituted 65.5% of NBU growths (205/313) and 50% of ICU growths (5/10). It constituted 17%, 15% and 14 %
of the growths in the pediatric wards (22/130), medical wards (13/88) and obstetrics/gynecology wards (1/7) respectively. There was no
K. pneumoniae isolated from the surgical wards (Fig i).The NBU K. pneumoniae isolates contributed 83% of all the hospital KP isolates
(205/281). The pediatric and medical wards contributed 8% and 5% of the hospital K. pneumoniae isolates respectively (Fig i). K.
pneumoniae was constantly a significant growth in the hospital over the 11 year period (Fig ii).
Table i: Demographic characteristics of patients with K. pneumoniae isolates at MTRH 2002-2013
NBU-New born unit; ICU- Intensive care unit
* Percentages reflect distribution of K. pneumoniae among the wards. 83% of the K. pneumoniae isolates originated from the NBU.
Table ii: K. pneumoniae resistance to antibiotic groups at MTRH 2002-2013
ANTIBIOTIC
GROUP
RESISTANT
n (%)
SENSITIVE
n (%)
INTERMEDIATE
n (%)
TOTAL NO
TESTED
Penicillin 226 (84.6) 37 (13.9) 4 (1.5) 267
Cephalosporins 511 (81.8) 90 (14.4) 24 (3.8) 625
Aminoglycosides 204 (49.2) 161 (38.8) 50 (12) 415
Macrolides 20 (87) 3 (13) 0 (0) 23
Carbapenems 44 (23.2) 143 (75.3) 3 (1.6) 190
Tetracyclins 38 (95) 2 (5) 0 (0) 40
Sulphonamides 79 (88.8) 9 (10.1) 1 (1.1) 89
Quinolones 50 (41.3) 71 (58.7) 0 (0) 121
Lincosamides 4 (80) 1 (20) 0 (0) 5
Vancomycin 29 (87.9) 4 (12.1) 0 (0) 33
Oxazolidinones 18 (75) 6 (25) 0 (0) 24
Minocycline 2 (40) 1 (20) 2 (40) 5
Chloramphenicol 46 (93.9) 3 (6.1) 0 (0) 49
Characteristics n (%)N=281
Age, yrs; mean(std) 4.8 (11.5)
Gender
Male 99 (35.2)
Female 182 (64.8)
Wards*
Adults 13 (5)
Pediatric 22 (8)
NBU 205 (83)
Obstetrics/Gynecology 1 (0)
ICU 5 (2)
Others 6 (2)
Apondi et al., Afr. J. Infect. Dis. (2016) 10(2): 89 – 95
DOI:10.21010/ajid.v10i2.3
91
Table iii: K. pneumoniae resistance pattern to specific antibiotics at MTRH 2002-2013
ANTIBIOTIC
GROUP
RESISTANT
n (%)
SENSITIVE
n (%)
INTERMEDIATE
n (%)
TOTAL NO
TESTED
Ceftriaxone 68 (87.2) 9 (11.5) 1 (1.3) 78
Ciprofloxacin 32 (44.4) 40 (55.6) 0 (0.0) 72
Gentamycin 106 (82.8) 19 (14.8) 3 (2.3) 128
Amikacin 48 (21.0) 135 (59.0) 46 (20.1) 229
Meropenem 8 (7.0) 106 (92.2) 1 (0.9) 115
Cefipime 105 (85.4) 12 (9.8) 6 (4.9) 123
Ceftazidime 108 (69.7) 37 (23.9) 10 (6.5) 155
* Ward distribution of K. pneumoniae isolates at MTRH. 83% of the isolates originated from the NBU.
** Prevalence of K. pneumoniae amongst all isolates within particular wards. K. pneumoniae constituted 66% of the NBU isolates and
50% of the ICU isolates.
Figure i: K. pneumoniae distribution within wards at MTRH 2002-2013
Figure ii: Prevalence of K. pneumoniae by year at MTRH 2002-2013 as a percentage of the total hospital blood culture isolates.
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Figure iii: K. pneumoniae resistance pattern to antibiotic groups over time at MTRH 2002-2013. Left pane showing trend for Penicilin,
Cephalosporins, and Carbapenems; Right pane showing trend for Aminoglycosides, Tetracyclins and Quinolones and Lincosamides
antibiotic groups
Figure iv: K. pneumoniae resistance pattern to individual antibiotics over time at MTRH 2002-2013. Left pane showing trend for
Ceftriaxone, Meropenem, Cefipime and Ceftazidimine; Right pane showing trend for Ciprofloxacin, Gentamycin and Amikacin
antibiotics.
Most of the isolates were multidrug resistant with highest resistance of over 80% to Penicillins, Cephalosporins, Macrolides,
Tetracyclines, Sulphonamides, Lincosamides and Chloramphenicol (Table ii). Aminoglycoside and quinolone resistance was at 49.2%
and 41.3% respectively. The lowest resistance rates were documented for Carbapenems (23.2 %). An analysis of the resistance levels to
individual commonly prescribed antibiotics indicated resistance of over 80% to Ceftriaxone, Cefipime, and Gentamycin (Table iii).
Amikacin and Meropenem had least resistance (21% and 7 % respectively).
We assessed for resistance pattern over the 11 year period for possible trends. Antibiotic class resistance pattern analysis
showed persistent high resistance (>70%) to Cephalosporins and Penicillins throughout the study period. Quinolone resistance was below
40% for the study period except for 2005-2007 when it peaked to above 80%. Cephalosporin resistance declined from 100% in the year
2002-2004 to below 10% for the next 6 years followed by an increase to 20% in the period 2011-2013 (Fig iii).
Among the Cephalosporins, resistance to Ceftriazone showed a steady rise over the study period from no resistance recorded in
2002-2004 to remain constantly above 70% for the remaining period. Resistance to Cefipime and Ceftazidime was high (above 50% and
60% respectively) throughout the study period. For the Aminoglycosides, Gentamycin resistance was constantly above 70% while that of
Amikacin dropped from above 70% at the beginning to below 20% in the last 6 years. Likewise, Meropenem resistance steadily reduced
from 100% resistance in the first 3 years to below10% in the last 6 years. Ciprofloxacin resistance was at 40% in the first 3 years, peaked
during the period 2005-2007 at 84.6% then rapidly declined thereafter.
Discussion
Klebsiella pneumonia is normal human intestinal enterobacteria. It is considered an opportunistic human pathogen and is
responsible for severe nosocomial infections in immunocompromised patients, in patients with prolonged hospital stay and in patients
with various implants (Adamski J et al., 2008; Mehrgan H et al., 2010; Velasco E et al., 2004) . It has been found to be a significant cause
of neonatal sepsis in the developing countries (Mathure NB et al., 2002; Stephen EM et al., 2013; Tiwari DK et al., 2013; Tumaini VM et
al., 2012) . In the developed world, multi drug resistant K. pneumoniae (MDR KP) has been documented to cause disease outbreaks
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leading to significant morbidity and mortality (Lee K et al., 2010; Patricia AB et al., 2004). It was the commonest pathogenic organism
isolated in our hospital during the study period and was most prevalent in the New Born Unit (NBU), the pediatric wards and Intensive
Care Unit (ICU). Most of the KP isolates were multidrug resistant with high resistance to Cephalosporins, Penicillins and Gentamycin,
relatively high resistance to the Quinolones and relatively moderate sensitivity to Carbepenems. Our study suggests a high prevalence of
MDRKP in the hospital with possible cross contamination between the wards.
MDR KBP has been found to be resistant to third generation Cephalosporins, Aminoglycosides and Quinolones but often
sensitive to Carbapenems (Bradford PA, 2001; Hirsch EB et al., 2010). In our study, resistance to Cephalosporins was very high (>80%
resistance) possibly due to widespread use of ceftriaxone especially in our NBU where the largest burden of this organism was present.
Ceftriaxone resistance increased rapidly during the study period to remain constantly above 70%. Cefipime and Ceftazidime, although
not frequently prescribed in our set up, had very high resistance throughout the study period. Cephalosporin resistance is conferred from
β-lactamase production, which is plasmid mediated and transferable to other Cephalosporins and to other gram negative
enterobacteriacea such as E. coli (Bradford PA, 2001; George AJ et al., 2005). Similar findings were documented in Tanzania where
Cefotaxime was the most prescribed antibiotic in the NBU resulting in high overall third generation Cephalosporin resistance (Stephen
EM et al., 2013). Data from Korea for the year 2007 showed lower Cephalosporin resistance rates than in our study (Cefotaxime 25%,
Cefepime 22%, Ceftazidime 29%, Cefoxitin 21%)) although during an ESBL KP outbreak Ceftazidime resistance rose to 47% (Lee K et
al., 2010; Roh KH et al., 2008) .
Development of bacterial resistance to Aminoglycosides has been documented to be slowest amongst the antibiotics (Rennie
RP et al., 1977). In Toronto, the first Gentamycin resistance was documented 7 years after first use (Curie K et al., 1978). This resistance
was transferrable to other Gram Negatives, particularly E. coli. Gentamycin is part of many first line regimens in both developed and
developing countries. In our hospital, it is often used as first line antibiotic in neonatal sepsis and has been used in the unit for over 10
years. It recorded a high level of resistance of 83% compared to Amikacin (21% resistance) which is preserved for second-line treatment.
In Korea, both Gentamycin and Amikacin had relatively lower resistance of about 30% (Lee K et al., 2010). Data from Tanzania was
similar to ours for Gentamycin (77% resistance) and slightly lower for Amikacin (1.45 % resistance) (Tumaini VM et al., 2012).
Gentamycin resistant KP species has been found to have higher carriage in the intestinal and urinary tracts and longer durations of
shedding than Gentamycin sensitive KP resulting in nosocomial hospital outbreaks (Hart CA et al., 1982).
K. pneumoniae resistance to Quinolones was 41.3% with Ciprofloxacin resistance being at 44.4 %. Similar findings were
reported in India where K. pneumoniae resistance to Ciprofloxacin amongst children below ten years was 35.71% (Tiwari DK et al.,
2013). In our study, Ciprofloxacin resistance reduced from over 80% in 2005-2007 to below 30% in 2011-2013 possibly due to reduction
in prescription in our hospital over that period. Quinolone resistance has been noted to be low in NBU compared to other wards due to
contra-indication of their use in newborns (n= 25, 38%, p<0.05) (Stephen EM et al., 2013). However, in our study Quinolone resistance
in the medical wards was lower than the over-all resistance (36.6% versus 44.4%). Quinolone resistance is plasmid mediated and
transferrable from person to person especially amongst patients with long hospital stay. Aminoglycoside exposure has been associated
with Quinolone resistance in K. pneumoniae and Pseudomonas aeruginosa, suggesting the need for awareness of the potential cross
resistance and thus failure of Quinolones in settings where there is widespread use of Aminoglycosides such as in our hospital
(Lautenbach E et al., 2001; Masuda N et al., 1992; Strausbaugh LJ et al., 1996).
The resistance to Carbapenems was lowest at 23.2%. Resistance to Meropenem was 7.0%. Carbapenem resistant K.
pneumoniae is considered the most resistant strain. Carbapenem resistance has been shown to result from changes in membrane
permeability, high β lactamase and Cephalosporinase levels and production of carbapenemases.  Evidence of carbapenemase production 
from a unit needs to be handled efficiently as they are associated with β lactamase production resulting in penicillin and cephalosporin 
resistance (Walsh TR et al., 2012). A prospective study of clinical enterobacteriacea isolates in Morocco found a Carbapenemase
production rate of 2.8% (Wartiti MA et al., 2012). Data from several European countries record rates of less than 1% except during
outbreaks where rates as high as 17-43% are recorded. (Chetcuti Z et al., 2014; Marina K et al., 2014) .In Kenya only seven Carbapenem
resistant K. pneumoniae were detected in a two years study at the Aga Khan University Hospital in Nairobi (Nordmann P et al., 2011).
Most of the isolates were from urine of adult patients in contrast to our study where the isolates were from blood cultures and
significantly from neonates. Our results indicate higher rates of Carbapenem resistance and this should be monitored with possible
genomic and epidemiologic studies to curb any further rise. There was 100% resistance to Meropenem in the period 2002-2004 (n=8) and
all the samples were from the NBU.
Diagnosis and treatment of MDR KP infections and colonization in our hospital and similar hospitals in the developing
countries is complicated. A multidisciplinary approach is necessary with teams including clinicians, pharmacists, and microbiologists
with support from the hospital management. Prevention of spread of resistance by proper aseptic procedures such as hand washing,
disinfection of equipment, reduction in ward congestion and isolation need to be intensified. Awareness on MDR organisms should be
raised. Early detection of MDR KP through routine surveillance with profiling of the resistance pattern should be encouraged to avoid
ineffective therapy in order curb the spread of the strain responsible for the outbreak. In one incidence in New York, increased use of
Ceftazidime in treatment of Acinetobacter infections resulted in an outbreak of Ceftazidime resistant K. pneumoniae, and it was after
detection that effective therapy was instituted (Kenneth SM et al., 1993). Attempts to reduce the multi-class resistance should also be
made to regain susceptibility to cheaper and more readily available drugs. Antibiotic restriction and rotation are possible options for
developing countries where access to newer antibiotics is limited. In the USA, an 80% reduction of hospital consumption of
Cephalosporins resulted in a 44.0% reduction in Ceftazidime-resistant K. pneumoniae infection and colonization throughout the medical
center (P<.01), a 70.9% reduction of cephalosporin resistance within all intensive care units (P<.001), and an 87.5% reduction within the
surgical intensive care unit (P<.001) within 1 year of restriction (Rahal JJ et al., 1998).
Conclusion
There was a high prevalence of MDR KBP isolates in our hospital with most of the isolates in the NBU. The isolates were
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highly resistant to third generation Cephalosporins and Gentamycin.
Recommendations
Stringent infection prevention control measures need to be instituted especially in the NBU to minimize the nosocomial spread
of MDRKP. In case of suspected or confirmed infection with MDRKP; Carbapenems are the drug of choice for treatment. Quinolones
and Amikacin may be considered where Carbapenems are unavailable. We also recommend further studies to characterize the molecular
genetic composition of MDR and Carbapenem resistant K. pneumoniae in our set up.
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